Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Clene Inc (NQ: CLNN )

0.3801 +0.0065 (+1.74%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,819,668
Open 0.4142
Bid (Size) 0.3800 (1)
Ask (Size) 0.3932 (38)
Prev. Close 0.3736
Today's Range 0.3618 - 0.4198
52wk Range 0.2500 - 1.020
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Analyst Scoreboard: 5 Ratings For Clene
Via Benzinga
Clene Inc. (NASDAQ: CLNN) CEO and CFO Present Corporate Updates and Future Plans at 72nd Emerging Growth Conference
Via Investor Brand Network

Performance

YTD
+29.29%
+29.29%
1 Month
+2.18%
+2.18%
3 Month
-5.24%
-5.24%
6 Month
-30.27%
-30.27%
1 Year
-61.99%
-61.99%

More News

Read More
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Delays in Diagnosing MS Highlight Need for More Awareness, Research
Via Investor Brand Network
Analyst Scoreboard: 6 Ratings For Clene
Via Benzinga
Why Oracle Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket
Via Benzinga
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) to Present at Emerging Growth Conference
Via Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Present at Emerging Growth Conference
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Announces Updates on ACT-EAP for CNM-Au8(R) Compassionate Use
Via Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Issues Update on NIH-Funded Program for CNM-Au8® in ALS
Via Investor Brand Network
Exposures Product Safety
Clene Inc. (NASDAQ: CLNN) Participates in Three Investor Conferences During May 2024, Promoting CNM-Au8(R) Neuronal Health Therapy
Via Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Looking to Transform Healthcare for Individuals with Neurodegenerative Diseases
Via Investor Brand Network
Study Identifies Genetic Link Between Parkinson’s, Inflammatory Bowel Disease
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Announces Key Operational Highlights as part of First Quarter 2024 Financial Results
Via Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Announces Participation Schedule for Upcoming May Conferences
Via Investor Brand Network
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Releases Q1 2024 Financial Numbers, Operation Highlights
Via Investor Brand Network
Exposures Product Safety
CLNN Stock Earnings: Clene Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
3 Speculative Penny Stocks Offering High-Upside Potential for Under a Buck
Via InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Study Suggests Metabolism Issues After Spinal-Cord Injury Result from Disturbed Neuronal Activity
Via Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Spotlighted in a Recent ‘From Lab to Launch’ Podcast Release
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Presents Findings on Phase 2 VISIONARY-MS LTE at American Academy of Neurology Annual Meeting
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Continues Development of Lead Drug Candidate CNM Au8(R) for Neurodegenerative Diseases including Parkinson’s Disease
Via Investor Brand Network
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.